Navigation Links
BioMed Realty Trust Declares First Quarter 2013 Common Stock Dividend

SAN DIEGO, March 18, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a first quarter 2013 dividend of $0.235 per share of common stock, The dividend is equivalent to an annualized dividend of $0.94 per common share.

The common stock dividend is payable on April 15, 2013 to stockholders of record at the close of business on March 28, 2013. 

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 13.2 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Francisco, Maryland, San Diego, New York/New Jersey, Pennsylvania and Seattle, which have well-established reputations as centers for scientific research.  Additional information is available at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company's domestic operations; risks associated with the company's investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
2. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
3. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
4. Fourth Annual Bay Area Biomedical Device Conference: March 27th, 2013 at San Jose State University
5. Foundation for the NIH Announces Lurie Prize Recognizing Outstanding Achievement by a Young Biomedical Scientist
6. Lou Paradise, President and Chief of Research, Topical BioMedics, Inc. Slated to Speak at Integrative Healthcare Symposium
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. BioMed Realty Trust Prices Public Offering Of 12,700,000 Shares Of Common Stock
10. ABIA Hires Biomedical Executive, Serial Entrepreneur as Chief Operating Officer
11. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
Post Your Comments:
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
(Date:11/30/2015)... Jose, CA (PRWEB) , ... ... ... Content Intelligence Company, today announced tighter software integration with MarkLogic, the Enterprise ... where organizations maximize information to drive change. , Smartlogic’s Content Intelligence capabilities ...
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
Breaking Biology News(10 mins):